IMiDs patent Pages on BioPortfolio:

BioPortfolio - Celgene Corporation
The IMiDs immunomodulatory drugs are an expanding family of compounds. ... US Patent No. Title. 6476052, Isoindolines, method of use, and pharmaceutical ...
http://www.bioportfolio.com/biocorporate/466-Celgene+Corpora...

BioPortfolio - Celgene Corporation
The IMiDs immunomodulatory drugs are an expanding family of compounds... 6th September, 2008 ... US Patent No. Title. 6479554, Immunotherapeutic agents ...
http://www.bioportfolio.com/biocorporate/466-Celgene_Corpora...

Results from other life science and pharmaceutical sites:

Celgene Provides Update On Clinical Pipeline
The IMiD pipeline is covered by a comprehensive intellectual property estate of U.S. and foreign issued patents and pending patent applications including ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

Oral Cancer Drug REVLIMID(R) Receives Marketing Authorization from ...
The IMiDs pipeline is covered by a comprehensive intellectual property estate of issued and pending patent applications in the US, EU and other regions, ...
http://biz.yahoo.com/bw/081006/20081006005519.html?.v=1...

Celgene Corporation Withdraws Revlimid Application In Europe ...
2 Jun 2008 ... The IMiDs pipeline is covered by a comprehensive intellectual property estate of issued and pending patent applications including ...
http://www.biospace.com/news_story.aspx?NewsEntityId=98427...

[Ibuprofen--a new application for pharmacological ...[Med Wieku ...
Kasprzaka 17a, 01-211 Warszawa, Polska. kpn@imid.med.pl. Patent ductus arteriosus (PDA) remains a frequent problem in premature infants, particularly
with ...
http://www.ncbi.nlm.nih.gov/pubmed/11328971...

CC-1088 Celgene Keith Dredge
IMiDs are structurally related, non-PDE4 inhibitors that .... The first Celgene patent referring to TNFα inhibitors (which ...
http://www.biomedcentral.com/content/pdf/cd-596608.pdf...

Thalidomide Analogues as Anticancer Drugs
Similar to thalidomide, IMiDs showed marked increases in IL-2 and ..... The initial patent application for these compounds, as well as related analogues,
...
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=20...

Advances in Anti-Arthritic Agents - SMi's Third Annual Conference ...
phthalimide fragment of the moiety, while the IMiDs are ..... patent filing by Arakis, which discloses the anti-malarial ...
http://www.biomedcentral.com/content/pdf/cd-457688.pdf...

REVLIMID(R) PDUFA Date Extended Three Months By FDA
The IMiD pipeline, including REVLIMID, is covered by a comprehensive intellectual property estate of U.S. and foreign issued and pending patent
applications ...
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=...

CC-5013 Celgene Constantine S Mitsiades & Nicholas Mitsiades*
of matter patent US-05635517 that covers the active. ingredient of CC-5013, and therapeutic uses of this and other. IMiDs [420496]. On 19 November 2002, ...
http://www.biomedcentral.com/content/pdf/cd-542660.pdf...

The IKK NF-[kappa]B system: a treasure trove for drug development ...
IMiD-induced apoptosis in multiple myeloma cells is associated with ..... pyridyl cyanoguanidines were reported in a recent patent as IKK inhibitors84, 85
. ...
http://www.nature.com/nrd/journal/v3/n1/full/nrd1279.html...

Home Marketing Services News Reports Company Profiles InDepth Drug Discovery Careers Conferences Videos Search Contact
	Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner. See User Agreement Send comments and feedback to: Peter Barfoot Managing Director, BioPortfolio Ltd. UK Tel: (+44) 1300 321501 USA Voicemail and Fax: (+1) 415 680 2472	All rights reserved. All other trademarks recognized. BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10 Copyright 1997-2008 - BioPortfolio Limited.